AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04041440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clEAR auditory training
Description: Children play auditory brain training computer games
Study NCT03243643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Description: HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Study NCT03243643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Study NCT01356641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment alone
Description: Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
Study NCT01356641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Appendectomy either open or laparoscopic depending on the surgeon's preference
Study NCT00003048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine Trihydrate
Description: Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
Study NCT02540395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (for Group B)
Description: Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
Study NCT02540395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF (mycophenolate mofetil) (for Group B)
Description: MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF.
Study NCT02540395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-methyl prednisolone (Steroids) (for Group B)
Description: At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed.
Study NCT02540395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (for Group A)
Description: The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption.
Study NCT02540395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycofenolate mofetil (MMF) (for Group A)
Description: Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation.
Study NCT02540395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-methyl prednisolone (Steroids) (for Group A)
Description: At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day.
Study NCT04418713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active video-games
Description: An intervention with active video-games to increase physical activity and improve body composition
Study NCT06062940 — intervention group
Intervention type: BEHAVIORAL
Intervention: SHARE Approach
Description: The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
Study NCT02917265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS for vagus stimulation
Description: TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
Study NCT02917265 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS for sham stimulation
Description: TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
Study NCT02891044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
Study NCT03885804 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Quadratus lamborum dexmedetomidine intravenous
Description: Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Study NCT03885804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lamborum dexmedetomidine perineural group(
Description: Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
Study NCT04404608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood picture, bone marrow aspiration cytology
Description: none except the regular routine investigations in such cases
Study NCT02430818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Study NCT02430818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Study NCT01199458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: 20 mikrogr/kg
Study NCT01199458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
Study NCT02966535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
Description: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
Study NCT02966535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
Description: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
Study NCT01821898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Budesonide
Description: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
Study NCT01821898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elimination diet
Description: This group will receive an elimination diet
Study NCT00692640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
Study NCT00692640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
Study NCT04000932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local platelet rich plasma (PRP) injection-T-Lab PRP kit
Description: Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
Study NCT04000932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local steroid injection-Diprospan ®, Schering Plough
Description: The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
Study NCT02743715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS (transcranial direct current stimulation)
Description: An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
Study NCT02743715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
Study NCT03290573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short peripheral venous catheter
Description: short peripheral venous catheter for infusion therapy in adult patients
Study NCT03290573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short peripheral venous catheter
Description: short peripheral venous catheter for infusion therapy in adult patients
Study NCT03266185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter PICT
Description: Shorter post-infusion cooling time
Study NCT03571984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving on ABC Plus
Description: The intervention has two components. CBT Moving on After Breast Cancer
Study NCT02881008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Study NCT02881008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Study NCT02885727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
Study NCT02885727 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
Study NCT02441946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02441946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Administered orally
Study NCT02441946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally
Study NCT02441946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Administered orally
Study NCT02441946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally
Study NCT02441946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Administered orally
Study NCT02131038 — intervention group
Intervention type: OTHER
Intervention: Medica device, drug-like
Description: Ectoin (R) Allergy Nasal Spray
Study NCT01719224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elevated body position
Description: 45 degrees elevated upper body position
Study NCT01719224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine body position
Description: non-elevated upper body position
Study NCT04112940 — intervention group
Intervention type: OTHER
Intervention: Starch-based Thickened Liquids
Description: Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
Study NCT04112940 — intervention group
Intervention type: OTHER
Intervention: Xanthan-gum Thickened Liquids
Description: Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
Study NCT01274065 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Description: The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
Study NCT02548858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineorrhaphy
Description: Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
Study NCT02548858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Perineorrhaphy
Description: Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
Study NCT03354130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets
Study NCT03354130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets
Study NCT03068806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
Study NCT05264233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: 50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
Study NCT05264233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
Study NCT05264233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable oil
Description: 50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
Study NCT02757222 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalated Dose
Description: Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy.
Study NCT02757222 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose
Description: CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy.
Study NCT03855410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S4E
Description: The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
Study NCT03855410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention-Matched Control Group
Description: Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
Study NCT01035333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: 60mg capsule three times a day for up to 6 months
Study NCT01333540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Escalating doses
Study NCT01333540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT01376960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective forefoot surgery
Description: Includes both soft-tissue and osseous procedures.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Study NCT00451555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
Study NCT00451555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.